1 / 9

The SYMPHONY Trial

The SYMPHONY Trial. Sibrafiban Versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Reference

austin-foster
Download Presentation

The SYMPHONY Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The SYMPHONY Trial Sibrafiban Versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant. 2005;20:2105–2112.

  2. Background Chronic kidney disease (CKD) is highly prevalent in patients with cardiovascular disease. We explored the associations of CKD with outcomes using combined data from two large acute coronary syndrome (ACS) trials. The associations of CKD with prescription patterns for common cardiovascular medications and the association of these prescription patterns with clinical outcomes were explored.

  3. Aim To compare sibrafiban and aspirin for protection offered in ischemic heart events post-ACS.

  4. Method • Study design: The SYMPHONY trial was a randomized double-blind study. • Study population: A total of 9233 patients participated in this trial. • Treatment regimen: 9233 patients were randomly assigned either aspirin orally 80 mg twice a day or sibrafiban either low dose or high dose twice daily for 90 days. In the 2nd SYMPHONY trial, patients were randomized to receive aspirin 80 mg orally, low-dose sibrafabin plus aspirin 80 mg, or high-dose sibrafabin alone twice daily. • End point: Death or myocardial infarction.

  5. Result 6840 patients had stage I, 5909 were categorized in stage II, 955 were in stage III and 3 were in stage IV. The study mostly involves females or older people who were non-smokers and had a co-morbid disease such as hypertension, congestive heart failure and diabetes mellitus. Patients with CKD usually receive cardiovascular medications less frequently. However, with increase in CrCl levels the risk of mortality was greatly reduced. The effect of medications on CKD and overall mortality is described by diagrams as given below.

  6. Conclusion CKD is an independent predictor of risk among ACS patients, and is associated with less frequent use of proven medical therapies. Patients with CKD usually receive cardiovascular medications less frequently. However, by increasing the CrCl levels the risk of mortality can be reduced. Chronic kidney disease (CKD) is highly prevalent and it is an independent predictor of death or MI among acute cardiovascular syndrome patients. CKD patients normally receive cardiovascular medications less frequently. The increase of CrCl levels will definitely reduce the risk of mortality in patients.

More Related